logo-loader

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

Published: 18:28 02 Mar 2023 EST

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (IT) cohorts in combination with Pembrolizumab. Overall the study aims to recruit up to 100 patients across around 10 trial sites in the United States and Australia. 

Imugene’s Phase 1b Azer-cel trial 57% complete response rate

Imugene Ltd (ASX: IMU, OTC: IUGNF) chief medical officer Dr. Paul Woodard and managing director and CEO Leslie Chong talked with Proactive’s Tylah Tully about the latest results from the Phase 1b clinical trial of Azer-cel, the company’s CD19 CAR-T therapy. Dr. Woodard, speaking from 2025...

on 02/13/2025
OSZAR »